Introduction {#s1}
============

Progressive renal decline is the clinical manifestation of the disease process underlying the development of diabetic nephropathy ([@B1],[@B2]). Although patients with chronic kidney disease (CKD) are at high risk for end-stage renal disease (ESRD), this risk varies tremendously. Some patients with CKD progress rapidly, whereas others may progress over a decade or more. In the absence of diabetic animal models that develop renal failure, observational studies in humans are valuable to search for new pathways to the development of drugs that would slow renal function decline and postpone ESRD.

The mechanisms responsible for this variation in patients with diabetes are studied with the use of newly developed high throughput omics technologies ([@B3]--[@B5]). Among these, metabolomic platforms have been used to search for new metabolic pathways ([@B3],[@B6]--[@B9]). Our global profiling study in type 2 diabetes (T2D) demonstrated that certain metabolites can be predictors of ESRD that occurs 10 years later independent of legacy markers such as albuminuria and baseline renal function ([@B3]). To date, no study to our knowledge has examined metabolomic profiles of patients with type 1 diabetes (T1D) who progress to ESRD, the ultimate outcome of diabetic nephropathy.

Research Design and Methods {#s2}
===========================

The Committee on Human Subjects of the Joslin Diabetes Center approved the informed consent and recruitment and examination procedures for this study.

Study Group {#s3}
-----------

Approximately 3,500 adult patients with T1D diagnosed before age 40 receive care at the Joslin clinic. Between 1991 and 2004, we monitored this population for the occurrence of persistent proteinuria by using routinely measured albumin-to-creatinine ratios (ACRs). Patients with persistent proteinuria were invited to participate in a follow-up study on the genetics of diabetic nephropathy ([@B2],[@B10]). Eligibility criteria included residence in New England and age at enrollment between 21 and 54 years. In that interval, persistent proteinuria was diagnosed in 790 eligible patients, and 564 (71%) participated in the Joslin Proteinuria Cohort Study. At study enrollment, a standardized baseline examination was performed by trained recruiters who administered a structured interview and brief physical examination. Blood and urine specimens collected at the baseline and follow-up examinations were stored at −85°C until analysis ([@B2],[@B10]).

Enrolled patients were followed until 2012. Blood and urine specimens were collected at least every 2 years. Collection of research specimens occurred during routine clinic visits. Patients with less frequent clinic visits were examined at their homes.

Among the patients enrolled in the Joslin Proteinuria Cohort Study, 199 had CKD of whom 158 were included in the current study. Of note, selection of the study participants was based purely on their baseline exposures and was independent from their follow-up characteristics.

Assessment of Abnormalities in Urinary Albumin Excretion {#s4}
--------------------------------------------------------

In the Joslin clinical laboratory, albumin concentrations in spot urines are routinely measured at least once a year. Between 1991 and 2009, urinary albumin concentrations were measured by immunonephelometry on a BN ProSpec System (Dade Behring, Newark, DE) with N-albumin kits. Creatinine measurements in urine were assayed by the Jaffe modified picrate method on a Ciba Corning 550 Express Plus Chemistry Analyzer. For each patient, the geometric mean ACR for the preceding 2-year interval of the baseline examination was determined to assign an albuminuria status: normoalbuminuria (ACR \<30 μg/g creatinine), microalbuminuria (ACR 30--300 μg/g creatinine), and proteinuria (\>300 μg/g creatinine) ([@B11]).

Assessment of Renal Function {#s5}
----------------------------

From 2011 to 2014, serum specimens obtained for research purposes at baseline (*n* = 520) and during follow-up (*n* = 1,560) in participants in the Joslin Proteinuria Cohort Study were used to measure creatinine concentrations. The measurements were performed in the Advanced Research and Diagnostic Laboratory at the University of Minnesota by using the Roche enzymatic assay (product no. 11775685) on a Roche/Hitache Mod P analyzer. This method is calibrated to be traceable to an isotope dilution mass spectrometry reference assay and was verified by measuring National Institute of Standards and Technology SRM 967.

In addition, we retrieved 2,900 measurements of baseline serum creatinine concentrations (*n* = 520) from Joslin clinical laboratory records. These measurements were assayed by the Jaffe modified picrate method as described above. For 633 samples, we used duplicate measurements to calibrate the Joslin clinical measurements to the assay method used at the University of Minnesota laboratory. The CKD Epidemiology Collaboration equation was used to determine the estimated glomerular filtration rate (eGFR) ([@B12]). For each participant, we used all available serial eGFR determinations performed during follow-up to determine eGFR slopes by general linear model procedure.

Ascertainment of Onset of ESRD {#s6}
------------------------------

All participants from the Joslin Proteinuria Cohort Study included in the current study were queried against rosters of the U.S. Renal Data System (USRDS) and the National Death Index (NDI), covering all events up to the end of 2012. USRDS maintains a roster of U.S. patients who received renal replacement therapy, which includes dates of dialysis and transplantation ([@B13]). The NDI is a comprehensive roster of dates and causes of deaths in the U.S. ([@B14]). ESRD was defined by a match with the USRDS roster or a listing of renal failure among the causes of death on an NDI death certificate.

Global Metabolomic Profiling {#s7}
----------------------------

Baseline serum specimens were subjected to global profiling (Metabolon, Durham, NC). The Metabolon platform uses gas chromatography and liquid chromatography mass spectrometry in positive and negative modes ([@B15],[@B16]). The liquid chromatography mass spectrometry portion of the platform incorporates a Waters ACQUITY UPLC system and a Finnigan LTQ mass spectrometer (Thermo Fisher Scientific), including an electrospray ionization source and linear ion trap mass analyzer. The gas chromatography column is 5% phenyl dimethyl silicone, and the temperature ramp is from 40°C to 300°C over 16 min. All samples were then analyzed on a Finnigan TRACE DSQ fast-scanning single-quadrupole mass spectrometer (Thermo Fisher Scientific) using electron impact ionization. After peak identification and quality control filtering, the metabolite-relative concentrations were obtained from median-scaled day-block normalized data for each compound. Samples in this study were run in batches balanced by case status.

Repeated Metabolomic Measurements Over Time {#s8}
-------------------------------------------

In the study group, we identified 20 participants with a stable diabetic nephropathy phenotype over time (eGFR slope \<2.5 mL/min/1.73 m^2^ per year, ACR ±200 mg/g creatinine per year) for whom we performed global metabolomics measurements in serum samples taken at baseline and 3--8 years later. Global profiling was performed according to the protocol described above. Samples from the same individuals were run on the same batch.

Comparison of Findings in Other Published Reports With Our Global Metabolomics Data {#s9}
-----------------------------------------------------------------------------------

We analyzed amino acids and purine and pyrimidine metabolites reported to be associated with diabetic nephropathy or eGFR decline that were also well detected in our main study by global metabolomic profiling ([@B3],[@B6],[@B8],[@B9],[@B17]). We evaluated their associations with eGFR slope and with progression to ESRD in the main study.

Measurements of Glycemic Control and Urinary Glomerular and Tubular Protein Markers {#s10}
-----------------------------------------------------------------------------------

HbA~1c~ was measured in the Joslin clinical laboratory according to the method calibrated to Diabetes Complications and Control standards. In addition to ACR, three other proteins were measured in baseline urine specimens. IgG2 was measured in the Joslin research laboratory as previously described ([@B18]). Neutrophil gelatinase-associated lipocalin (NGAL) was measured in the Joslin research laboratory by Quantikine ELISA (DLCN20; R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. KIM-1 was measured in the laboratory of J.V.B. (Brigham and Women's Hospital) ([@B19],[@B20]). Measurements of protein-based markers (IgG2, KIM-1, and NGAL) were available for 91 study participants. The interassay coefficient of variation was \<20% for all analytes. All the urine specimens for marker measurements had the same number of freeze-thaw cycles.

Auxiliary Study of Renal Clearance {#s11}
----------------------------------

Among 365 Joslin Proteinuria Cohort Study participants who had normal renal function at baseline (eGFR \>60 mL/min/1.73 m^2^), 21 who had progressed to ESRD were selected and matched by age, sex, and baseline renal function with 32 participants who had an eGFR \<−3.3 mL/min/1.73 m^2^ (nonprogressors) ([@B2],[@B11]). Measurements of the metabolites were performed according to a similar protocol, the global profiling used in the main study. Mass spectra were compared with the library of ∼1,000 purified standards for their analytical identification, whereas measurements performed in the main study were compared with the library of 2,400 standards.

Data Analysis {#s12}
-------------

Differences in clinical characteristics were tested by ANOVA for continuous variables and χ^2^ test for categorical variables. Metabolites detected by global profiling in at least 80% of the study participants were considered in further analysis. Correlations of the metabolites with baseline eGFR, other baseline measures, and subsequent eGFR slopes were expressed as Spearman rank correlation coefficients. Adjustment for multiple comparisons was performed with a positive false discovery rate (q-value \<0.05 for significance). An independent effect of a metabolite for the progression to ESRD was estimated by using a Cox proportional hazards regression model. After transformation of the metabolite concentration to normally distributed ranks, its effect on risk of progression was expressed as the hazard ratio (HR) per 1 SD difference ([@B3]). Discrimination abilities of the risk prediction models were evaluated with C statistics ([@B21]). Principal component (PC) analysis was used as a data reduction approach to create a metabolite index. Reproducibility of metabolomic measurements over time was determined by intraclass correlation coefficients (ICCs), which represent ratios of between-person variance to the sum of the within- and between-person variances (modified ICC_SAS macro). Data analysis was performed with SAS 9.4 and JMP Pro 12.0.0 software (SAS Institute, Cary, NC).

Results {#s13}
=======

Characteristics of the Study Group {#s14}
----------------------------------

Five hundred sixty-four patients attending the Joslin clinic were recruited into the Joslin Proteinuria Cohort Study. Of these patients, 158 with eGFR 30--60 mL/min/1.73 m^2^ at enrollment were selected for this study. Median follow-up for this study was 11.5 years. Follow-up for participants in whom ESRD did not develop was 4.4--21 years and was understandably shorter (2.4--17.3 years) for participants in whom ESRD did develop. During this time, ESRD developed in 99 participants (63%). Median eGFR slope was −5.0 (−8.4 to −2.5) mL/min/1.73 m^2^ per year. Participants with more-rapid eGFR decline were younger and had diabetes for a shorter period, worse glycemic control, and higher albuminuria. They differed slightly with regard to their baseline eGFR. Clinical characteristics of the study group according to tertiles of eGFR slope distribution are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics of the study group stratified by the rate of the renal function decline

                                                                  Renal Function Decline                                                 
  --------------------------------------------------------------- ------------------------ --------------------- ----------------------- -----------
  At baseline                                                                                                                            
   Male \[*n* (%)\]                                               25 (47)                  28 (53)               29 (46)                 0.38
   Age (years)                                                    45 ± 10                  42 ± 8                40 ± 10                 0.003
   Duration of diabetes (years)                                   30 ± 8                   29 ± 8                27 ± 9                  0.007
   HbA~1c~ (%)                                                    8.5 ± 1.3                9.3 ± 1.6             9.6 ± 1.7               0.005
   HbA~1c~ (mmol/mol)                                             69 ± 14                  78 ± 18               81 ± 19                 0.005
   Serum cholesterol (mg/dL)                                      191 ± 43                 219 ± 63              219 ± 71                0.03
   Systolic blood pressure (mmHg)                                 134 ± 20                 136 ± 19              137 ± 24                0.57
   Diastolic blood pressure (mmHg)                                75 ± 11                  79 ± 11               80 ± 11                 0.07
   Antihypertensive/renoprotective treatment (%)                  93                       92                    80                      0.07
   ACR (μg/g creatinine)                                          670 (403, 1,009)         1,007 (680, 1,934)    1,533 (748, 3,526)      0.0004
   eGFR (mL/min/1.73 m^2^)                                        50 ± 12                  48 ± 13               44 ± 13                 0.02
  Follow-up                                                                                                                              
   Length (years)                                                 14.4 (9.7, 18.4)         11.8 (7.7, 13.8)      9.2 (5.6, 12.1)         \<0.001
   Annual eGFR slope (mL/min/1.73 m^2^)                           −1.9 (−1.0 to −2.5)      −5.0 (−3.9 to −5.9)   −10.9 (−8.5 to −15.6)   By design
   Incidence of ESRD                                                                                                                     
    Cases (*n*)                                                   16                       35                    48                      \<0.001
    Rate per 1,000 person-years[\*](#t1n1){ref-type="table-fn"}   1.1 (0.6, 1.9)           3.7 (2.6, 5.1)        10.5 (7.7, 13.9)        \<0.001

Data are mean ± SD or median (25th, 75th percentile) unless otherwise indicated.

\*Incidence rate of ESRD is accompanied by 95% CI.

Metabolomic Profiles Associated With Variation in eGFR Slope {#s15}
------------------------------------------------------------

### Multivariate Analysis {#s16}

Global metabolomic profiling resulted in the detection of mass spectra of 123 metabolites. Of those, 110 were detected in at least 80% of the participants (87 amino acids and 23 purine and pyrimidine metabolites), and we designated them as commonly detected. Eleven metabolites were significantly associated with eGFR slope in the analysis adjusted for multiple testing, and nine of them (81%) were modified metabolites. Overall, the metabolomic platform's coverage included 39 modified metabolites featuring five types of modifications: acylation, C-glycosylation, carbamoylation, sulfation, and methylation. Metabolites of all types of modifications, except for methylation, contained numerous biochemicals associated nominally with nephropathy progression. Nine modified metabolites remained significant in the analysis adjusted for multiple testing. C-glycosyltryptophan, N6-carbamoylthreonyladenosine, and O-sulfotyrosine were the top-three metabolites, of which higher levels were associated with a more-rapid eGFR slope. All nine significant modified metabolites correlated with baseline eGFR at a nominal significance level (*P* \< 0.05) ([Fig. 1*A*](#F1){ref-type="fig"}).

![Associations of metabolites with subsequent renal function decline. *A*: Global matrix of correlation coefficients of all commonly detected amino acids and nucleotides (*n* = 114) with baseline eGFR (*x*-axis) and with a subsequent eGFR slope (*y*-axis). Each mark represents a correlation coefficient of an individual metabolite. Modified metabolites are represented as open shapes (blue □, C-glycosylated; red △, sulfated; orange ○, acylated; green ◇, carbamylated; purple bars, methylated). All the remaining metabolites are presented as ●. *B*: Score plot of PC1 and PC2 based on nine significant candidate metabolites identified in the global matrix analysis. Marks represent individual study participants with renal function decline in the bottom tertile of the eGFR slope distribution (decliners) and those in the top tertile of the eGFR slope distribution (nondecliners). The labels of the *x*- and *y*-axes include the explained variance. CGST, C-glycosyltryptophan; CRE, creatinine; N6CA, N6-carbamoylthreonyladenosine; NATHR, N-acetylthreonine; OST, O-sulfotyrosine; PSD, pseudouridine.](dc160173f1){#F1}

A PC analysis of all well-detected metabolites (*n* = 114) explained only a small proportion of the overall variance. PC1~all~ explained 15.5% of the variance, and PC2~all~ explained only 7.1%. Score plots of all PCs with eigenvalues \>1 were examined and did not separate well decliners from nondecliners (data not shown). Of note, top loadings contributing to the PC1~all~ corresponded with the nine significant modified metabolites identified in the global matrix analysis. In the further PC analysis that considered only these nine metabolites, PC1~9~ was the only component with an eigenvalue \>1 and explained 68.3% of the variance. Contributions to PC1~9~ were comparable among these metabolites, except for N6-acetyllysine and phenol sulfate, for which the loadings were lower. The related PC score plot decently separated decliners from nondecliners ([Fig. 1*B*](#F1){ref-type="fig"}). PC1~9~ correlated significantly with eGFR slope (*r* = −0.28).

The multivariate analysis did not reveal a predictive value of essential amino acids or branched chain amino acid--related metabolites for renal function decline. Creatinine was the top metabolite associated with baseline eGFR, but only moderately correlated with the subsequent eGFR slope. Analysis of ratios of modified metabolites (products) to their respective substrates did not improve risk predictions over the effects of the sole modified metabolites (data not shown). Associations of all detected metabolites with eGFR slope and their interrelationships expressed as loadings are listed in [Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-0173/-/DC1).

Modified Metabolites as Candidate Biomarker Predictors of Progression to ESRD {#s17}
-----------------------------------------------------------------------------

### Multivariable Analysis {#s18}

We used a Cox proportional hazards regression model to examine the independence of associations of the modified metabolites with risk of progression to ESRD. All nine modified metabolites associated with eGFR slope were also associated significantly with progression to ESRD in the Cox proportional hazards regression model after controlling for the covariates HbA~1c~, ACR, and eGFR. Seven of the nine metabolites (except for N-acetylalanine and phenol sulfate) remained significant in the fully adjusted model, controlled for an expanded panel of clinical covariates ([Fig. 2](#F2){ref-type="fig"}). Discrimination ability of the clinical model measured by C-index was 0.706. The addition of each significant metabolite (one at a time) increased the C-index from 0.708 to 0.722. Seven significant metabolites correlated among each, with nonparametric correlation coefficients ranging from *r* = 0.45 to *r* = 0.89 (*P* \< 0.0001 for each) ([Fig. 3](#F3){ref-type="fig"}). The C-index of the Cox model containing a metabolite index derived from PC1~9~ and controlled for clinical covariates increased to 0.728, but an improvement in the discrimination ability did not reach statistical significance.

![Nine modified metabolites significant in the global multivariate analysis as candidate biomarkers for progression to ESRD. Reproducibility over time is expressed as ICCs. HRs are presented per 1 SD of the metabolite. Partially adjusted HRs are controlled for baseline HbA~1c~, ACR, and eGFR. Fully adjusted HRs are controlled for blood pressure, BMI, smoking status, HbA~1c~, ACR, eGFR, uric acid levels, treatment with renin-angiotensin system inhibitors, other antihypertensive treatment, and statins.](dc160173f2){#F2}

![Matrix of correlation coefficients among and between modified metabolites and baseline indices of diabetic kidney injury: glycemic control (HbA~1c~), glomerular markers (ACR, IgG2), and tubular markers (KIM-1, NGAL). Cell color indicates strengths and directions of the correlations from red (positive correlation) to white (no correlation) to blue (negative correlation).](dc160173f3){#F3}

### Within-Individual Reproducibility Over Time {#s19}

Repeated measurements of well-detectable metabolites over a median of 5 years demonstrated that 36% of amino acids (31 of 87) and 13% of purine and pyrimidine metabolites (3 of 23) had at least fair reproducibility over time (ICC \>0.3) (global data not shown). Among the nine modified metabolites significant in the multivariate analysis, pseudouridine tracked very well over time (ICC 0.74 \[95% CI 0.48, 0.88\]). Reproducibility of C-glycosyltryptophan, O-sulfotyrosine, and N-acetylthreonine was fairly good (ICC 0.34--0.38) and was poor for the remaining five metabolites ([Fig. 2](#F2){ref-type="fig"}).

### Metabolite Levels in the Study Participants Compared With Subjects Without Nephropathy {#s20}

We compared levels of the nine significant modified metabolites in the multivariate analysis between the study participants with T1D, proteinuria, and CKD (main study) and 20 subjects with T1D, normoalbuminuria, and median diabetes duration of 24 years. Ratios of metabolites in the main study participants compared with that in subjects with normoalbuminuria ranged from 1.21 to 1.94 (*P* \< 0.05 for each comparison) (data not shown).

### Candidate Metabolite Biomarkers Across Independent Cohort Studies {#s21}

We identified 13 metabolites measured in the current study that were formerly reported to be associated with nephropathy phenotype in other independent metabolomics studies ([@B3],[@B6],[@B8],[@B9],[@B17]). C-glycosyltryptophan and pseudouridine, O-sulfotyrosine, and tryptophan metabolites were reproducibly associated with renal outcome in this and at least one other independent study ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-0173/-/DC1)).

Modified Metabolites as Potential Contributors to Diabetic Nephropathy Progression {#s22}
----------------------------------------------------------------------------------

### Modified Metabolites Versus Glycemic Control and Kidney Injury Markers At Baseline {#s23}

We created a matrix of the correlation coefficients between the nine significant modified metabolites in the multivariate analysis and baseline measurements of HbA~1c~ (glycemic control), markers of glomerular damage (urinary excretion of albumin and IgG2), and markers of tubular damage (urinary excretion of KIM-1 and NGAL). All nine modified metabolites were also correlated, to at least a moderate degree, with baseline eGFR (*r* = −0.48 to −0.3). The pattern of associations with markers of tubular injury (KIM-1 or NGAL) mirrored associations observed with a baseline eGFR, except for N-acetylthreonine, N6-acetyllysine, and phenol sulfate, whose associations were notably weaker. Associations of the metabolites with ACR and IgG2 were absent or weak ([Fig. 3](#F3){ref-type="fig"}).

### Renal Clearance of the Modified Metabolites and Risk of Progression to ESRD {#s24}

To elucidate whether an increase in metabolites in participants with proteinuria and CKD is not due to impaired clearance, we conducted an auxiliary study of subjects with comparable proteinuria but normal renal function for whom we evaluated metabolite levels in plasma and urine according to the nephropathy risk. Clinical characteristics of the auxiliary study subjects are presented in [Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-0173/-/DC1). Median follow-up for the auxiliary study subjects was 12.3 years. Follow-up for nonprogressors was 6.9--21 years and 2.4--19 years for ESRD progressors. The library of the metabolomic platform in the auxiliary study had less comprehensive coverage than the main study because only four significant modified metabolites were measured. Risk patterns remained similar to that observed in the main study. The auxiliary study was small; therefore, confidence intervals around HRs were understandably broader. Of note, in the excretion patterns analysis, metabolites measured in urine or measured as fractional excretions were not significantly associated with progression to ESRD ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-0173/-/DC1)).

We also compared free acetyllysine with circulating proteomic content of acetyllysine in a subset of subjects. We did not observe a significant correlation between the two. These results suggest that circulating acetyllysine residues do not likely reflect proteolysis of circulating proteins ([Supplementary Data](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-0173/-/DC1)).

Conclusions {#s25}
===========

This study was conducted in a cohort of patients with T1D, proteinuria, and CKD stage 3 at baseline who were followed for approximately a decade to assess eGFR trajectories and identify time to onset of ESRD. To our knowledge, this and our former study in T2D ([@B3]) are the only to date that evaluated the associations of circulating metabolomic profiles with progression to the ultimate outcome of diabetic nephropathy: ESRD.

In the current study, global metabolomic profiling revealed nine candidate metabolite biomarkers as potential risk factors of progression to ESRD in T1D. These metaboites were C-glycosyltryptophan, pseudouridine, O-sulfotyrosine, N-acetylthreonine, N-acetylserine, N6-carbamoylthreonyladenosine, N6-acetyllysine, N-acetylalanine, and phenol sulfate. The effect of these metabolites on risk of ESRD remained independent after adjustment for glycemic control, renal function, and albuminuria. Seven of these nine (except for N-acetylalanine and phenol sulfate) remained significant in multivariable models adjusted for a comprehensive selection of clinical covariates. C-indices of models containing added biomarkers were higher than the C-index of the clinical model alone, but improvements in the discrimination abilities of models were not significant, likely reflecting that the study may not have had sufficient power because of the number of applied adjustments.

Do these findings have the potential for generalization? This report and two others (Joslin Kidney Study in T2D \[[@B3]\] and Cooperative Health Research in the Region of Augsburg \[KORA\] F4 \[[@B9]\]) have reported that C-glycosyltryptophan, pseudouridine, and O-sulfotyrosine are among the top risk metabolites that predict GFR-based renal outcome. KORA F4 evaluated incident CKD in the general population, and all three studies used the same metabolomic platform. The Framingham cohort study used a different platform ([@B6]) wherein the authors identified tryptophan derivatives as determinants of incident CKD. Tryptophan-derived metabolites also reached nominal significance in the current study.

Do the candidate metabolites actually contribute to disease progression? This study demonstrates that significant modified metabolites markedly correlate with one another and further with baseline indices of kidney tubular injury. We hypothesize that a common, currently unknown mechanism leads to an increase in these modified metabolites in circulation and that these metabolites may be toxic to kidney tubules, contributing to subsequent eGFR loss. Functional studies are needed to validate such a hypothesis.

The presence of impaired renal clearance at baseline in the current study raises concerns about whether retention can account for increased serum levels of metabolites ([@B9],[@B22]--[@B24]). Nevertheless, effects of metabolites were independent from baseline renal function in the multivariable models examined. Second, we provide limited evidence that renal clearances of the selected modified metabolites were unaltered with regard to ESRD risk.

One may speculate that an increase in significant metabolites may also be due to the increased posttranslational modifications in tissues of patients at risk. Increased glycosylation, sulfation, acetylation, and carbamoylation of amino acids and proteins have been reported in diabetic and uremic tissues ([@B25]--[@B28]). The importance of the circulating metabolites rather than their urinary levels suggests sources other than the kidney, such as liver and muscle. No studies to our knowledge have systematically examined the content of modified metabolites across tissues in the presence of diabetes. However, basic research studies have demonstrated that the modification of metabolites identified in the current study have been determined in many tissues of subjects without diabetes, including kidney, liver, and muscle ([@B27]--[@B35]). A number of studies also have highlighted the importance of modifications of metabolites in the presence of chronic diabetic complications ([@B25]--[@B28],[@B34],[@B36]--[@B38]). Different modifications are involved in a variety of biological processes, such as inflammation ([@B36],[@B37]), glucose metabolism ([@B34],[@B35]), and epigenetic regulation ([@B38]), among others.

Finally, we must consider the strengths and limitations of the current study. The study was conducted in Caucasians, so it may not be generalizable to populations of other ethnic ancestry. Our study is novel because the modified metabolites were studied as risk factors for subsequent progression of diabetic nephropathy; on the contrary, in past cross-sectional comparisons, posttranslational modifications in diabetic complications were evaluated as features associated with an already-present disease. The current study includes a well-characterized population with a long follow-up and ascertainment of ESRD together with eGFR slopes. Associations of the metabolites also were concordant between two renal outcomes and in other studies in T2D and the general population ([@B3],[@B6],[@B9]). Future replication in independent prospective cohorts of T1D is needed to validate these predictive associations in patients with this disease phenotype. An important advantage of the nontargeted metabolomic approach utilized in our study is that it examines metabolites comprehensively and assigns a ranking to identified metabolic alterations. For example, not all modifications were associated with disease progression (acetylation was, whereas methylation was not).

In summary, the metabolomic approach is an attractive line of investigation in diabetes because of the metabolic nature of the disease. It is relevant in kidney disease because the kidney is involved in handling numerous metabolites, and the metabolites themselves may contribute further to kidney injury. We report associations of metabolomic determinants with risk of ESRD in T1D. Future directions should involve elucidating mechanisms that underlie increased acetylation or C-glycosylation of metabolites in patients at increased risk for renal disease, whereas independent replication studies will expand our knowledge about the potential generalizability of the current findings.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-0173/-/DC1>.
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